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Background
Nonalcoholic fatty liver disease (NAFLD) affects 40% to 85% 
of patients with chronic hepatitis C (1, 2). This correlation ap-
pears to depend on host and viral factors (3). Recent studies 
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ABSTRACT
Background: Nonalcoholic fatty liver disease develops in patients with chronic hepatitis C. 
Interferon and ribavirin combination therapy is the standard treatment for chronic hepati-
tis C, but if present, NAFLD can reduce the virological response to anti-HCV therapies. 
Objectives: We determined whether the addition of rosuvastatin to interferon and ribavirin 
improves the sustained virological response (SVR) and reduces steatosis.
Patients and Methods: This study was a prospective, randomized, open-label trial. Between 
January 2004 and December 2007, 65 patients with chronic hepatitis (27 women and 38 
men, mean age 48 years) aged 32-63 years (median 46 years) were consecutively enrolled. 
Patients were randomly assigned to receive leukocyte interferon alpha (3 MIU 3 times per 
week) plus ribavirin (1200 mg per day) for 12 months or interferon alpha and ribavirin at the 
same dosages plus rosuvastatin (5 mg per day). The primary endpoints were measurements 
in SVR, liver enzyme, cholesterol, triglyceride, CRP, glucose, and insulin levels; and Homa-IR, 
fibrosis, and steatosis scores.
Results: After 12 months of treatment, we observed a significant improvement in SVR in 51% 
of patients who received interferon plus ribavirin plus rosuvastatin compared with 18% of 
relapsers (OR 1.52; 95% CI= 0.41-5.64; RR 1.13). There were 23 responders (69%) and 10 nonre-
sponders (30%) (OR 1.38; 95% CI= 0.49-16.5; RR 1.11). When comparing interferon plus ribavi-
rin group vs interferon plus ribavirin and rosuvastatin group after 12 months, we observed 
a significant difference in AST (85.70 vs.106.5.00 IU/ml) (OR 1.2; 95% CI= 0.29-4.94; RR 1.04; 
p<0.001), ALT (81.80 vs. 126.2 IU/ml) (OR 1.2; 95% CI= 0.29-4.94; RR 1.04; p<0.001), LDL-cho-
lesterol (0.01 vs. 0.60 mmol/l) (OR 14; 95% CI= 3.98-49.16; p RR 2.96; <0.001), triglycerides 
(0.17 vs. 0.2 mmol/l) (OR 20; 95% CI= 4.94-80.89; RR 5.38; p<0.05), and Viremia (1.8 vs. 2.48 
UI/ml, p<0.05). Mean fibrosis score decreased 0.10 vs. 0.50 (OR 4.5; 95% CI= 0.89-22.66; RR 
1.5; p<0.05), and mean steatosis score declined 0.30 vs. 0.50 (OR 11.2; CI= 2.88-43.53; RR 2.75; 
p<0.001).
Conclusions: In HCV patients with NAFLD, the addition of rosuvastatin to interferon and rib-
avirin significantly reduces viremia, steatosis, and fibrosis without causing side effects.
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  Implication for health policy/practice/research/medical education:
Inflammatory pathways are implicated in  increased vascular risk. The involvement of cytokine-related signaling pathways in inflammatory 
diseases has prompted the development of many therapeutic strategies aimed at their modulation to limit disease severity and progres-
sion. Modulation of these pathways would similarly alter the inflammatory processes related to accelerated atherosclerosis so cytokines 
that determine an increase of cholesterol and tryglicerides levels represent cardiovascular risk factor. In this trial we focused on the role of 
rosuvastatin and especially its role in reducing steatosis, fibrosis and inflammation and because of that in reducing cardiovascular risk. New 
treatment regimen needs very special attention of all clinicians involved in the treatment of HCV patients. We suggest reading this article to 
all clinicians in the fields of gastroenterology and infectious diseases.
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have suggested that interactions between hepatitis C virus 
(HCV) core protein and lipid droplets are required for the 
HCV infection cycle. In infected cells, the HCV core protein 
associates with the surface of lipid droplets. This interaction 
also appears to be linked directly to virus-induced steato-
sis, which entails the deposition of triglycerides in the liver 
and accelerates the progression of fibrosis in patients with 
chronic hepatitis C (4). Many clinical studies have reported 
that virus-induced steatosis is significantly more severe in 
those with HCV genotype 3 than with other genotypes (5). 
Some  virus  that  is  recovered  from  the  blood  of  infected 
patients  binds  to  host  lipoprotein  particles  that  contain 
apolipoprotein B100 (apoB100) and apolipoprotein E (apo 
E), the predominant proteins in VLDL. These viral RNA host 
lipoprotein  complexes  are  called  lipo-viro-particles  (LVPs) 
(6). Recent reports indicate that the nascent virus and host 
lipoprotein form LVPs in the endoplasmic reticulum of he-
patoma cells, which is necessary for release of the virus. The 
formation of LVPs might favor viral infectivity or persistence 
in the host and can interfere with the normal secretion or 
uptake of host cell lipoproteins and mediate the pathology 
of persistent viral infection (7). Consequently, HCV-infected 
patients, whether they have NAFLD, develop a chronic and 
progressive disease that sometimes responds poorly to treat-
ments (8, 9). Statins inhibit hepatitis C viral RNA replication 
in vitro with nearly the same efficacy as the most potent 
clinical therapeutics (10). Ikeda et al. used a genome-length 
HCV RNA replication system to evaluate the anti-HCV activity 
of statins and their effects in combination with interferon α. 
In the study by Ikeda et al. five statins were examined: ator-
vastatin, fluvastatin, pravastatin, simvastatin, and lovasta-
tin. Atorvastatin, fluvastatin, and simvastatin had stronger 
anti-HCV activity, and pravastatin exhibited no such activity, 
although it inhibited HMG-CoA reductase. Because fluvasta-
tin had the most robust anti-HCV activity, it was examined 
in combination with interferon-α, demonstrating synergis-
tic inhibitory effects on HCV RNA replication (10). Recently, 
another study demonstrated that fluvastatin has anti-hep-
atitis C virus activity by inhibiting the geranylgeranylation 
of  cellular  proteins  synergistically  with  interferon-α  (11). 
Nevertheless,  statins  upregulated  low-density  lipoprotein 
(LDL) receptor, which is required for HCV cell entry, and the 
closely related scavenger receptors SRBI and CD36. Aizaki et 
al. reported that lovastatin, an HMG-CoA reductase inhibitor, 
impeded HCV RNA replication in HCV replicon-harboring 
cells (11). Ikeda et al. also demonstrated that lovastatin sup-
pressed HCV RNA replication. These reports suggest that the 
anti-HCV activity of lovastatin results from the inhibition 
of protein geranylgeranylation rather than of cholesterol 
synthesis. In vivo LDL levels are a prognostic indicator of sus-
tained viral response to interferon in patients with HCV in-
fection, suggesting that lipid-lowering agents favor HCV en-
try into hepatocytes, effecting higher viral replication (12). 
Moreover, clinicians have been reluctant to use statins as a 
treatment for human hepatitis C trials due to their poten-
tial hepatotoxicity in chronic liver disease (13, 14). These con-
cerns were addressed by a recent trial, which demonstrated 
that high doses of pravastatin were safe and well tolerated 
(15). Of the statins, rosuvastatin is a hydrophilic statin that 
potentially has limited access to nonhepatic cells due to low 
passive diffusion and undergoes robust hepatic cell uptake 
via selective organic anion transport.
Objectives
The aim of this study was to determine whether the addi-
tion of rosuvastatin to interferon and ribavirin increases the 
sustained virological response (SVR) and if it reduces steato-
sis by improving hepatic histology.
Patients and Methods
Study Design
This 12-month, randomized, placebo-controlled trial was 
performed per the Declaration of Helsinki (16) and was ap-
proved by the local ethics committee. It was conducted in 
the Department of Internal Medicine, Cannizzaro Hospital, 
University  of  Catania,  Catania,  Italy.  All  patients  provided 
written informed consent before participating in the study. 
Eligible patients were randomly assigned equally to one of 
the two study treatments by a computer-generated table of 
random numbers, allocated in our central unit. They were di-
vided into 2 groups (A and B) and stratified by HCV genotype 
(1 vs. others) and viral load (≤600,000 IU/ml vs. >600,000 
IU/ml). Group A received leukocyte interferon alpha 3 MIU 
(Alfaferone; Alfa Wasserman Italy) intramuscularly 3 times 
per week for 12 months plus daily oral ribavirin (800 mg 
for body weight below 60 kg, 1000 mg between 60 and 75 
kg, and 1200 mg above 75 kg). Group B received leukocyte 
interferon alpha and ribavirin at the same dosages, route, 
and duration plus rosuvastatin 5 mg per day. Patients were 
evaluated before treatment and 2 weeks, 6 months, and 12 
months after initiation of the therapy. A follow-up evalua-
tion was performed 6 months after the end of the planned 
treatment. A medical interview and physical examination 
were conducted for all patients before therapy was begun.
Patients
Between January 2004 and December 2007, 65 patients 
with chronic hepatitis (27 women and 38 men, mean age 48 
years) aged 32-63 years (median 46 years) were consecutively 
enrolled (32 patients in the interferon and ribavirin group; 
33 patients in the interferon and ribavirin plus rosuvastatin 
group) (Table 1-2). The patients had to meet the following 
inclusion  criteria:  alanine  aminotransferases  (ALT)  levels 
greater than 1.5-fold higher than the upper limit of normal, 
the presence of anti-HCV antibodies in the serum, HCV-RNA 
>1000 copies/ml, and histological changes on the liver bi-
opsy. Exclusion criteria were: positivity for serum hepatitis 
B surface antigen, positive serum HIV antibody test, negativ-
ity for HCV antibodies, alcoholic liver disease (daily alcohol 
consumption <20 g/day), and diabetes. The presence of oth-
er  causes  of  hepatopathy,  decompensated  cirrhosis,  preg-
nancy, formal contraindications for interferon or ribavirin 
therapy (such as hemoglobinopathies, cardiopathy, hemo-
cromatosis, diabetes mellitus, autoimmune diseases, major 
depression  and  any  other  severe  psychiatric  pathological 
condition) and use of an illicit treatment or drug that might 
have influenced serum lipid levels within the last 12 months 
were causes for exclusion. Baseline demographics and histo-
logical findings on the liver biopsy were similar between the 
2 treatment groups. The mean times since chronic hepatitis 
C infection were comparable. The most frequent viral geno-
type was 1 b. Baseline viremia was similar in the 2 groups. Rosuvastatin reduces NAFLD in HCV patients 94 Malaguarnera M et al.
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ALT, AST, prothrombin time, total cholesterol, triglycerides, 
fasting plasma glucose, CRP, insulin, and HOMA-IR did not 
differ between groups.
Laboratory exams
A complete routine chemical workup, measuring red cell 
count,  hemoglobin,  white  cell  count,  platelet,  prothrom-
bin time, fasting plasma glucose, insulin, CRP, blood urea 
nitrogen, serum creatinine, bilirubin, alanine aminotrans-
ferase,  aspartate  aminotransferase,  alkaline  phosphatase, 
γ-glutamil transpeptidase, and creatin phosphokinase lev-
els, was performed at every medical visit. We also measured 
total  cholesterol,  HDL-cholesterol,  low-density  lipoprotein 
cholesterol (LDL-C), and triglycerides at baseline, 2 weeks, 6 
and 12 months, and the follow-up visit. An enzymatic assay 
was used to determine serum total cholesterol and triglycer-
ides levels (Hitachi 704 analyser–twin TG/CHO reactive, Boeh-
ringer Mannheim automated analysis, Germany). HDL-C was 
measured  by  another  enzymatic  assay  after  precipitating 
lipoproteins  that  contained  apolipoprotein  B  with  phos-
photungstic  acid/magnesium  chloride.  LDL-C  levels  were 
calculated using Friedewald’s method (17). Serum-sensitive 
C-reactive protein (CRP) was measured by particle-enhanced 
immunoturbidimetric  assay  (detection  limit  0.04  mg/L; 
Roche Diagnostics Mannheim Germany). Anti-HCV antibod-
ies were measured using a second-generation ELISA (Ortho-
Diagnostic Systems, Raritan NJ, USA), and positive samples 
were been confirmed by immunoblot (RIBA; Chiron Corpo-
ration, Emeryville, CA-USA). We measured serum HCV-RNA 
levels  by  quantitative  (Cobas  Amplicor  HCV  Monitor  test, 
version 2.0) and qualitative tests (Cobas Amplicor HCV test, 
version 2.0; limit of detection 50 IU/ml). HCV genotypes and 
subtypes were determined by a modified specific line probe 
assay (Inno-LiPA system; Innogenetics NV, Zwijnaarde, Bel-
gium), as described by Stuyver et al (18). The HCV genotypes 
were designated based on the nomenclature proposed by 
Simmonds (19).
Histology
Liver biopsy was performed in the 6 months before the ini-
tiation of therapy and 6 months after the end of treatment 
by modified Menghini technique. The specimen was fixed in 
4% neutral formaldehyde solution for routine histological 
processing and evaluation. The Knodell and Ishiak Histologi-
cal activity index (HAI) score was used to assess the histologi-
cal grade of the disease (20). Steatosis was graded on a scale 
from 0 to 4, based on the percentage of cells with fat—0 = 
none, 0.5 (trace) to <5%; 1 = 5% to < 25%; 2 = 25% to <50%; 3 = 
50% to <75%; and 4 = 75% to 100%. The pathologist was blinded 
to the treatment arms. The fibrosis stages were: 0 = no fibro-
sis, 1 = portal fibrosis without septa; 2 = portal fibrosis with 
rare septa; 3 = numerous septa without cirrhosis; and 4 = cir-
rhosis. The degree of steatosis was assessed based on the per-
centage of hepatocytes that contained fat droplets.
Efficacy and safety assessment
All enrolled patients were included in the intention-to-
treat  efficacy  analysis  (ITT),  and  patients  who  received  at 
least 1 dose of interferon-α plus ribavirin were included in 
the safety analysis. Data were analyzed using an intention-to-
treat principle. We considered patients to be “sustained viro-
logical responders” (SVRs) when HCV RNA was not detected 
(< 50 IU/ml) in serum at the end of the follow-up period. Re-
lapse was defined as undetectable HCV-RNA levels at the end 
of treatment but detectable levels during the follow-up pe-
riod. Adverse events were assessed by interviews and labora-
tory and clinical examinations during treatment. They were 
graded as mild, moderate, and severe based on WHO score. 
The treatment was halted if severe events occurred, such 
as hematological toxicity, hepatic failure, and lack of com-
pliance. In moderate and mild cases of adverse effects, the 
dose was reduced 50%, until resolution of the event, at which 
point a full dose was restarted.
Statistical analysis
Results  are  expressed  as  means  ±  standard  deviations. 
Comparisons of quantitative data were made by Student’s t-
test or Mann-Whitney test. Qualitative data were analyzed by 
chi-square test. A p-value <0.05 indicated a statistically sig-
nificant difference. All data management and statistical cal-
culations were performed using SPSS 15.0 (Chicago, IL, USA). 
Results
In the group that was treated with interferon plus riba-
virin,  AST  (p<0.001)  and  ALT  (p<0.001)  levels  decreased 
significantly in 46% of patients after 12 months. CRP levels 
(p<0.001),  insulin  (p<0.05),  HOMA-IR  (p<0.001),  and  vire-
mia  fell  significantly  (p<0.001).  Moreover,  mean  inflam-
matory score (p<0.05) and status scores declined (p<0.05). 
The  same  results  were  observed  at  the  follow-up.  In  the 
group that was treated with interferon plus ribavirin and 
rosuvastatin,  AST  (p<0.001)  and  ALT  (p<0.001)  levels  de-
creased in 54% of patients after 12 months. Total cholesterol 
(p<0.05), LDL-cholesterol (p<0.05), CRP (p<0.001), HOMA-IR 
(p<0.001), and viremia also fell significantly (p<0.001). At 
the follow-up time we observed a decrease in AST (p<0.001), 
ALT  (p<0.001),  LDL  cholesterol  (p<0.05),  CRP  (p<0.001), 
HOMA-IR (p<0.001), and plasma glucose (p<0.05) (Table 2). 
Mean  inflammatory  score  (p<0.001),  mean  fibrosis  score 
(p<0.05), steatosis score (p<0.001) also declined (Table 3). 
When comparing interferon plus ribavirin group vs interfer-
on plus ribavirin and rosuvastatin group after 12 months, we 
observed a significant difference as concerns the decrease in 
AST 85.70 vs. 106.5.00 IU/ml (OR 1.2; 95% CI= 0.29-4.94; RR 1.04; 
p<0.001), ALT 81.80 vs. 126.2 IU/ml (OR 1.2; 95% CI= 0.29-4.94; 
RR 1.04; p<0.001), LDL cholesterol 0.01 vs. 0.60 mmol/l (OR 
14; 95% CI= 3.98-49.16; RR 2.96; p<0.001), Triglycerides 0.17 
vs. 0.2 mmol/l (OR 20; 95% CI= 4.94-80.89; RR 5.38; p<0.05). 
Viremia values decreased significantly (p <0.05) (1.8 vs. 2.48 
UI/ml).  Therefore  we  observed  a  significant  difference  as 
concerns the increase in CRP 7.04 vs. 4.01 mg/dl (p<0.001), 
plasma glucose 6.18 vs. 5.84 mmol/l (p<0.05), HOMA-IR 5.38 
vs. 4.38 (p<0.001), insulin 19.6 vs. 16.9 mIU/L (p<0.05). After 12 
months, after treatment with interferon plus ribavirin plus 
rosuvastatin, SVR improved in 17 patients versus 13 patients 
who were treated with interferon plus ribavirin (51% vs. 40%), 
in 6 versus 7 relapsers, respectively (18% vs. 21%) (OR 1.52; 95% 
CI= 0.41-5.64; RR 1.13; p<0.05), in 23 versus 20 responders, re-
spectively (69% vs. 62%), and in 10 versus 12 nonresponders, 
respectively (30% vs. 37%) (OR 1.38; 95% CI= 0.49-16.5; RR 1.11; 
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Parameter 
(Normal Value)
Group A 
(IFNα and Ribavirin)
Group B 
(IFNα and Ribavirin+Rosuvastatin)
p-value
N 32  33
Age (year) 47.4 ± 5.2 47.8 ± 5.9 NS
Gender (M/F) 18/14 20/13 NS
Time since exposure (year) 5.08 ± 3.4 5.12 ± 3.6 NS
BMI (Kg/m2) 25.8 ± 3.6 26.8 ± 3.0 NS
Probable exposure (No of patients)
Blood transfusion 14 13 NS
Infected needle 6 7 NS
Healthcare environment 2 2 NS
Other/unknown 10 11 NS
Genotype
1a 3 3
1b 23 23
2a 2 1
3a 4 6
Laboratory parameter
Glucose (mmol/L) 
(normal: 3.9-6.4)
5.97 ± 0.48 6.01 ± 0.54 NS
Insulin (mIU/L) 
(normal: <19)
17.0 ± 5.1 17.6 ± 5.0 NS
HOMA-IR 4.51 ± 0.24 4.70 ± 0.32 NS
AST (IU/L) 
(normal: 15-50)
167 ± 34 164 ± 40 NS
ALT (IU/L) 
(normal: 15-50)
169 ± 47 170 ± 38 NS
Cholesterol (mmol/l) 
(normal: 0-5.2)
5.11 ± 0.66 5.12 ± 0.64 NS
Triglycerides (mmol/l) 
(normal: 0.3-2.8)
2.36 ± 0.50 2.28 ± 0.58 NS
Viremia (106 copies/ml) 5.04 ± 3.86 5.00 ± 3.44 NS
CRP (mg/dl) 
(normal: <1.0)
3.21 ± 0.62 3.31 ± 0.57 NS
vs interferon plus ribavirin and rosuvastatin group after 12 
months, we observed a significant difference as concerns the 
decrease in mean fibrosis score 0.10 vs. 0.50 (OR 4.5; 95% CI= 
0.89-22.66; RR 1.5; p<0.05), and mean steatosis score 0.30 vs. 
0.50 (OR 11.2; CI= 2.88-43.53; RR 2.75; p<0.001). Baseline ala-
nine aminotransferase values, normal fasting glucose, and 
rosuvastatin treatment were predictors of SVR in the univar-
iate analysis, but no predictors were independently associ-
ated with SVR in the multivariate analysis.
Adverse events
No  serious  adverse  events  (World  Health  Organization 
grade 3 or 4) were reported in the 2 groups. Six patients 
who were treated with interferon plus ribavirin and 2 in the 
other group experienced mild psychological disorders, such 
as anxiety, irritability, and depression. Median hemoglobin 
concentration  fell  significantly  during  the  first  3  months 
of treatment in both groups and stabilized for 3 months, 
returning to near-baseline values within 3 months after the 
end of the treatment. Notably, hemoglobin values decreased 
to a greater extent in the interferon plus ribavirin group. In 
patients  who  were  treated  with  interferon  plus  ribavarin 
plus  rosuvastatin,  median  hemoglobin  concentration  fell 
from 13.1 g/dl (range 11.2-14.0 g/dl) to 11.3 (range 10.4-14.0 g/
dl) at the end of therapy. The patients who were treated with 
interferon plus ribavirin experienced a decrease in median 
hemoglobin concentration from 13.0 g/dl (range 11.4-15.1) to 
10.5 g/dl (range 10.0-12.4 g/dl) at the end of therapy. The in-
terferon plus ribavirin group showed a significant decrease 
in white cell blood count. Platelet counts did not change sig-
nificantly in either group. Furthermore, both groups experi-
enced anorexia (12% in interferon plus ribavirin patients and 
16% in the interferon plus ribavirin plus rosuvastatin group), 
nausea (20% and 24%, respectively), weight loss (14% and 5%, 
respectively), headache (44% and 48%, respectively), fatigue 
(44% and 55%, respectively), myalgia (30% and 55%, respective-
ly), musculoskeletal pain (30% and 42%, respectively), irrita-
bility (18% and 22%, respectively), hypertriglyceridemia (34% 
and  18%,  respectively),  hypercholesterolemia  (24%  and  8%, 
respectively), and hyperglycemia (12% and 4%, respectively). 
Sixty-two percent of patients adhered to their medication 
dose and duration of therapy.
Discussion
Effective management of chronic HCV infection is criti-
cal (21). The goal of treatment for chronic HCV infection is 
sustained virological response (SVR), accompanied by im-
provements in liver damage. The potential benefits of SVR 
are decreased infectivity, prevention of liver damage, and 
improved necroinflammation. Long term, SVR may decrease 
one’s risk of developing cirrhosis, decompensation, and HCC; 
prolong survival; and improve quality of life (22-25). The cur-
rent standard of hepatitis C treatment is the combination of 
pegylated interferon-α (Peg- interferon-α) with ribavirin. This 
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regimen has been successful in patients with HCV genotype 
2 and 3 infections, effecting HCV eradication rates of 75% to 
90%. However, it is much less effective in patients with geno-
type 1 and 4 infections, yielding eradication rates that range 
from 45% to 52%. Recent studies on HCV replicons have impli-
cated statins as therapeutics for chronic HCV infection. The 
effect of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase 
inhibitors on HCV replication in human subjects has been 
examined prospectively in studies, with contrasting results. 
Some studies noted no reduction in HCV RNA titers relative 
to baseline levels (26-29), whereas other studies observed an 
unsustained, non-dose-related reduction in HCV RNA titers 
(29, 30).
We demonstrated significant beneficial effects of oral ro-
suvastatin, added to interferon alpha and ribavirin, on lipid 
metabolism, inflammation markers, status, and fibrosis. The 
effects persisted after 12 months and at the follow-up visit, 
and  patients  with  HCV  tolerated  rosuvastatin  well.  More-
over, viremia declined in both groups, but rosuvastatin had 
a greater effect when added to interferon and ribavirin com-
pared with interferon plus ribavirin alone. We hypothesize 
that because status negatively influences the response rate 
to antiviral treatment, as shown in large clinical trials, the 
management of status in chronic hepatitis C patients can 
improve the success of pharmacological interventions (31). 
The combination of rosuvastatin, interferon alpha, and riba-
virin appears to be more efficacious than interferon-α plus 
ribavirin in the treatment of ongoing NAFLD in patients with 
chronic hepatitis C. Rosuvastatin improves lipid profiles, he-
patic parameters, and the histology of HCV. In patients with 
HCV, rosuvastatin decreases total cholesterol, LDL, and trig-
lyceride levels and reduces CRP, status, fibrosis, and inflam-
mation (32). Moreover, rosuvastatin limits the effects of cy-
tokines, improving insulin resistance. Interleukin 1 and TNF, 
produced by monocytes and macrophages after stimulation 
with interferon, induce inflammation and increase serum 
triglyceride levels by stimulating hepatic lipogenesis, which 
promotes ongoing infections and progressive damage (33-
36). Thus, the antagonism of rosuvastatin against lipid me-
tabolism and fat accumulation is a new therapeutic mecha-
nism that can be used to improve antiviral therapies.
Statins  might  have  indirect  antiviral  effects  through 
mechanisms that are unrelated to lipid metabolism, sug-
gesting that statins have a place in the management of HCV 
patients. Nevertheless, they carry a risk of elevated asymp-
tomatic liver enzymes and hepatotoxicity, necessitating cau-
tious use in patients with fatty liver disease and hepatitis 
(37). In conclusion, our results suggest that statins, such as 
There were no significant differences between groups at baseline.
a NS: not significant; AST: Aspartate Amino Transferase; ALT: Alanine Amino Transferase; HDL: High-Density Cholesterol Lipoprotein; LDL: Low-Density Cholesterol Lipopro-
tein; CRP: C-Reactive Protein
Variable   
Group A
 (interferon α+Ribavirin) 
n=32
Group B 
(interferon α+Ribavirin+Rosuvastatin) 
n=33
P-value Group A 
vs. Group B b
Before
 treatment
After 
treatment
Follow-up
Before 
treatment
After 
treatment
Follow-up
After 
treatment
Follow-
up
AST (IU/ml) a 146.1 ± 49.8
60.4 ± 38.0 
  p<0.01
78.2 ± 38.6 
  p<0.001
145.0 ± 46.8
38.5 ± 30.2 
  p<0.001
50.0 ± 34.1 
  p<0.001
p<0.001 p<0.001
ALT (IU/ml) a  160.0 ± 49.4
78.2 ± 40.2 
  p<0.001
84.6 ± 46.1 
  p<0.001
184.0 ± 49.2
57.8 ± 21.4 
p<0.001
78.4 ± 28.8
  p<0.001
p<0.001 NS a
Total 
Cholesterol 
(mmol/L)
5.11 ± 0.8
5.0 ± 0.9 
  NS a
5.0 ± 0.7 
  NS a 5.2 ± 0.7
4.6 ± 0.8 
  p<0.05
4.9 ± 0.9
  NS a NS a NS a
HDL (mmol/L) a 1.06 ± 0.8
1.07 ± 0.8 
  NS a
1.04 ± 0.9 
  NS a 1.08 ± 0.8 1.1 ± 0.2 NS
1.05 ± 0.7
  NS a NS a NS a
LDL (mmol/L) a 2.50 ± 0.73
2.51 ± 0.64 
  NS a
2.5 ± 0.6 
  NS a 2.6 ± 0.78
2.0 ± 0.8
  p<0.05
2.2 ± 0.7 
  p<0.05
p<0.001 NS a
Triglycerides 
(mmol/L) 2.24 ± 0.71
2.41 ± 0.61 
  NS a
2.8 ± 0.74 
  NS a 2.2 ± 0.8
2.0 ± 0.4 
  NS a
2.1 ± 0.6 
  NS a p<0.05 p<0.001
Viremia 
(106 copies/ml) 3.24 ± 1.22
1.44 ± 0.87 
  p<0.001
2.10 ± 0.98 
  p<0.001
3.44 ± 1.18
0.96 ± 0.70
  p<0.001
1.33 ± 0.87
  p<0.001
p<0.05 p<0.001
CRP (mg/dl) a 3.24 ± 0.56
7.04 ± 0.61 
  p<0.001
5.21 ± 0.44
  p<0.001 3.43 ± 0.47
4.01 ± 0.61
  p<0.001
1.96 ± 0.32
  p<0.001
p<0.001 NS a
Plasma
 Glucose 
(mmol/L)
5.87 ± 0.67
6.18 ± 0.67 
  NS
5.91 ± 0.71 
  NS a 5.96 ± 0.71
5.84 ± 0.56 
  NS a
5.47 ± 0.51 
  p<0.05
p<0.05 p<0.05
Insulin (mIU/ml) 17.06 ± 5.0
19.6 ± 4.8 
  p<0.05
17.9 ± 6.2 
  NS a 17.44 ± 5.1
16.9 ± 5.4
  NS a
16.0 ± 5.2
  NS a P<0.05 NS a
HOMA-IR 3.14 ± 0.15
5.38 ± 0.14 
  p<0.001
4.02 ± 0.18  
   p<0.001         
4.56 ± 0.16
4.38 ± 0.14 
  p<0.001
3.88 ± 0.12
  p<0.001
p<0.001 p<0.001
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Variable
Group A 
(IFN α+Ribavirin) 
n=32
Group B 
(IFN α+Ribavirin+Rosuvastatin) 
n=33
p-value Group A vs. 
Group B
Before 
treatment
After treat-
ment
P-value Before 
treatment
After treat-
ment
P-value Baseline After treat-
ment
Mean Inflamma-
tion Score (range)
7.4 ± 2.6 (5-11) 6.0 ± 2.4(4-10) <0.05 7.7 ± 2.8 (5-11) 6.0 ± 2.0 (3-9) <0.001 NS <0.05
Mean Fibrosis 
Score (range)
1.6 ± 0.3 (1-4) 1.5 ± 08 (1-4) NS 1.5 ± 0.4 (1-4) 1.0 ± 0.8 (0-4) <0.05 NS NS
Steatosis 
Score(range)
2.3 ± 0.4 (1-4) 2.0 ± 0.4 (1-4) <0.05 1.9 ± 0.3 (1-4) 1.4 ± 0.5 (0-4) <0.001 NS <0.001
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